Malariaprophylaxe und Notfalltherapie in der Schwangerschaft – Aktuelle Datenlage und Empfehlungen

Louise Roggelin; Jakob P Cramer

doi:10.1055/s-0033-1347078

Flugmedizin · Tropenmedizin · Reisemedizin - FTR, Table of Contents

Geburtshilfe Frauenheilkd 2013; 20(3): 134-139
DOI: 10.1055/s-0033-1347078

Tropenmedizin

Malariaprophylaxe und Notfalltherapie in der Schwangerschaft – Aktuelle Datenlage und Empfehlungen

Malaria prevention and stand-by therapy during pregnancy –Current data situation and recommandations

Louise Roggelin

¹Sektion Tropenmedizin, 1. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf (Leitung: Prof. Dr. Gerd-Dieter Burchard) und Arbeitsgruppe Klinische Forschung, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg

,

Jakob P Cramer

¹Sektion Tropenmedizin, 1. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf (Leitung: Prof. Dr. Gerd-Dieter Burchard) und Arbeitsgruppe Klinische Forschung, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg

› Author Affiliations

Abstract

Eine Malariainfektion ist in der Schwangerschaft ein ernst zu nehmendes Risiko für Mutter und Kind, sodass schwangeren Frauen von einer Reise in Malariagebiete grundsätzlich abgeraten werden sollte. Kann eine Reise nicht verschoben werden, so ist ein konsequenter Expositionsschutz inklusive der Nutzung von Repellentien und medikamentöse Malariaprophylaxe für schwangere Reisende unabdingbar.

Im Allgemeinen wird Mefloquin als Prophylaxe und Notfalltherapie in der Schwangerschaft empfohlen. Chloroquin ist aufgrund der weltweiten Resistenzen nur bedingt einsetzbar. Im Falle einer Notfalltherapie in Gebieten mit hohen Resistenzraten gegen Mefloquin kann wohl Artemether-Lumefantrin empfohlen werden. Grundsätzlich ist aber zu sagen, dass vor allem für das erste Trimenon die Datenlage für alle aktuell verfügbaren Antimalariamedikamente unzureichend ist.

Malaria infections during pregnancy pose a serious risk for mother and child, so that pregnant women are generally advised not to travel to regions where malaria is endemic. Is it not possible for a pregnant woman to cancel or postpone her travel, it is indispensable for her to use efficient prophylaxis against malaria including repellents and antimalarials. In general mefloquine is recommended as prophylaxis and stand-by therapy rather than anything else. In areas with high resistance against mefloquine, arthemeter-lumefantrine should be considered as an option. Nevertheless it should be noted, that especially for the use of antimalarials during the first three month of pregnancy data is still insufficient.

Key words

malaria - pregnancy - prophylaxis - stand-by

Full Text

References

Literatur
1 World Tourism Organization UNWTO Im Internet: http://www2.unwto.org/
2 Desai M, ter Kuile FO, Nosten F et al. Epidemiology and burden of malaria in pregnancy. Lancet Infec Dis 2007; 7: 93-104
3 Rogerson SJ. Malaria in pregnancy and the newborn. Adv Exp Med Biol 2010; 659: 139-52
4 Umbers AJ, Aitken EH, Rogerson SJ. Malaria in pregnancy: small babies, big problem. Trends Parasitol 2011; 27: 168-75
5 Whitty CJ, Edmonds S, Mutabingwa TK. Malaria in pregnancy. BJOG 2005; 112: 1189-95
6 Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit. Schwangere Frauen. Im Internet http://www.dtg.org/schwangere.html
7 Koren G, Matsui D, Bailey B. DEET-based insect repellents: safety implications for children and pregnant and lactating women. CMAJ 2003; 169: 209-12
8 McGready R et al. Safety of the insect repellent N,N-diethyl-M-toluamide (DEET) in pregnancy. Am J Trop Med Hyg 2001; 65: 285-9
9 Antwi FB, Shama LM, Peterson RK. Risk assessments for the insect repellents DEET and picaridin. Regul Toxicol Pharmacol 2008; 51: 31-6
10 Chen T, Burczynski FJ, Miller DW et al. Percutaneous permeation comparison of repellents picaridin and DEET in concurrent use with sunscreen oxybenzone from commercially available preparations. Pharmazie 2010; 65: 835-9
11 Astroff AB, Young AD, Holzum B et al. Conduct and interpretation of a dermal developmental toxicity study with KBR 3023 (a prospective insect repellent) in the Sprague-Dawley rat and Himalayan rabbit. Teratology 2000; 61: 222-30
12 Steketee RW, Wirima JJ, Slutsker L et al. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg 1996; 55 (Suppl. 01)
13 Nosten F, ter Kuile F, Maelankiri L et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis 1994; 169: 595-603
14 Schlagenhauf P, Blumentals WA, Suter P et al. Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy. Clin Infect Dis 2012; 54
15 Vanhauwere B, Maradit H, Kerr L. Post-marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy. Am J Trop Med Hyg 1998; 58: 17-21
16 Phillips-Howard PA, Steffen R, Kerr L et al. Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. J Travel Med 1998; 5: 121-6
17 Villegas L, McGready R, Htway M et al. Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial. Trop Med Int Health 2007; 12: 209-18
18 McGready R, Ashley EA, Moo E et al. A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. J Infect Dis 2005; 192: 846-53
19 McGready R, Stepniewska K, Edstein MD et al. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur J Clin Pharmacol 2003; 59: 545-52
20 Na-Bangchang K, Manyando C, Ruengweerayut R et al. The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. Eur J Clin Pharmacol 2005; 61: 573-82
21 Phillips-Howard PA, Wood D. The safety of antimalarial drugs in pregnancy. Drug Saf 1996; 14: 131-45
22 Manson JD. Tetracyclines and the teeth. Lancet 1966; 1: 1104-1104
23 Czeizel AE, Rockenbauer M. Teratogenic study of doxycycline. Obstet Gynecol 1997; 89: 524-8
24 Hellgren U, Rombo L. Alternatives for malaria prophylaxis during the first trimester of pregnancy: our personal view. J Travel Med 2010; 17: 130-2
25 Manyando C, Kayentao K, D'Alessandro U et al. A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy. Malar J 2012; 11: 141-141
26 Manyando C, Mkandawire R, Puma L et al. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar J 2010; 9: 249-249
27 Rijken MJ, McGready R, Phyo AP et al. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Antimicrob Agents Chemother 2012; 55: 5500-6
28 Rijken MJ, McGready R, Boel ME et al. Dihydroartemisinin-piperaquine rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. Am J Trop Med Hyg 2008; 78: 543-5
29 Centers for Disease Control and Prevention. Choosing a Drug prevent malaria. Updated October 3, 2011. Im Internet: http://www.cdc.gov/malaria/travelers/drugs.html
30 Health Protection Agency. Guidelines for Malaria Prevention in Travellers from the United Kingdom. 2007. Im Internet: http://www.hpa.org.uk/webc/HPAweb File/HPAweb_C/1203496943523
31 World Health Organization. Guidelines for the treatment of Malaria. Second Edition 2010. Im Internet: http://www.whqlibdoc.who.int/publications/2010/ 9789241547925_eng.pdf